Nutra Pharma Corporation’s (NPHC) Growth Model Thrives in Managing a Multitude of Infectious Diseases
Nutra Pharma Corporation (OTCQB: NPHC) subsidiary Designer Diagnostics focuses its energy on designing and developing medical devices. Established in 2005, the company builds shareholder value by marketing and selling rapid diagnostics test kits for infectious diseases such as tuberculosis (TB) and nontuberculous mycobacteria (NTM). Designer Diagnostics test kits deliver cost effective and efficient, low infrastructure solutions for identifying and testing the sensitivity of NTM that have the ability to utilize paraffin wax as a sole carbon source or those that are hydrophobic. Designer Diagnostics also delivers an efficient solution for the rapid identification and sensitivity testing of TB. Designer Diagnostic’s…